Loading...

We've got a brand new version of Simply Wall St! Try it out

Evelo Biosciences

Nasdaq:EVLO
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EVLO
Nasdaq
$196M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. The last earnings update was 12 days ago. More info.


Add to Portfolio Compare Print
  • Evelo Biosciences has significant price volatility in the past 3 months.
EVLO Share Price and Events
7 Day Returns
12.1%
NasdaqGS:EVLO
-0.2%
US Biotechs
-1%
US Market
1 Year Returns
-50.9%
NasdaqGS:EVLO
-8.1%
US Biotechs
-0.4%
US Market
EVLO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Evelo Biosciences (EVLO) 12.1% -22.3% -22.8% -50.9% - -
US Biotechs -0.2% -0.2% 2.4% -8.1% 5.9% 2.8%
US Market -1% -3.3% 0.4% -0.4% 30.4% 37.1%
1 Year Return vs Industry and Market
  • EVLO underperformed the Biotechs industry which returned -8.1% over the past year.
  • EVLO underperformed the Market in United States of America which returned -0.4% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Evelo Biosciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Evelo Biosciences. This is due to cash flow or dividend data being unavailable. The share price is $6.11.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Evelo Biosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Evelo Biosciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:EVLO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in USD $-2.27
NasdaqGS:EVLO Share Price ** NasdaqGS (2019-08-16) in USD $6.11
United States of America Biotechs Industry PE Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 19.43x
United States of America Market PE Ratio Median Figure of 3,095 Publicly-Listed Companies 17.23x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Evelo Biosciences.

NasdaqGS:EVLO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:EVLO Share Price ÷ EPS (both in USD)

= 6.11 ÷ -2.27

-2.69x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Evelo Biosciences is loss making, we can't compare its value to the US Biotechs industry average.
  • Evelo Biosciences is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Evelo Biosciences's expected growth come at a high price?
Raw Data
NasdaqGS:EVLO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.69x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-20.3%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 0.76x
United States of America Market PEG Ratio Median Figure of 2,124 Publicly-Listed Companies 1.4x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Evelo Biosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Evelo Biosciences's assets?
Raw Data
NasdaqGS:EVLO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in USD $3.12
NasdaqGS:EVLO Share Price * NasdaqGS (2019-08-16) in USD $6.11
United States of America Biotechs Industry PB Ratio Median Figure of 424 Publicly-Listed Biotechs Companies 2.85x
United States of America Market PB Ratio Median Figure of 5,265 Publicly-Listed Companies 1.7x
NasdaqGS:EVLO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:EVLO Share Price ÷ Book Value per Share (both in USD)

= 6.11 ÷ 3.12

1.96x

* Primary Listing of Evelo Biosciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Evelo Biosciences is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Evelo Biosciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Evelo Biosciences has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Evelo Biosciences expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-20.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Evelo Biosciences expected to grow at an attractive rate?
  • Unable to compare Evelo Biosciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Evelo Biosciences's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Evelo Biosciences's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:EVLO Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:EVLO Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -20.3%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 23.1%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:EVLO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:EVLO Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 0 -150 -189 3
2022-12-31 0 -88 -139 3
2021-12-31 0 -79 -119 3
2020-12-31 0 -78 -103 3
2019-12-31 0 -74 -85 4
NasdaqGS:EVLO Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-06-30 -61 -73
2019-03-31 -57 -68
2018-12-31 -47 -61
2018-09-30 -40 -55
2018-06-30 -33 -49
2018-03-31 -27 -40
2017-12-31 -23 -34
2016-12-31 -12 -15

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Evelo Biosciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Evelo Biosciences is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:EVLO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Evelo Biosciences Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:EVLO Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -3.59 -2.56 -4.97 3.00
2022-12-31 -2.84 -1.64 -3.99 3.00
2021-12-31 -2.61 -1.98 -3.23 3.00
2020-12-31 -2.40 -1.92 -2.72 3.00
2019-12-31 -2.45 -2.33 -2.58 4.00
NasdaqGS:EVLO Past Financials Data
Date (Data in USD Millions) EPS *
2019-06-30 -2.27
2019-03-31 -2.36
2018-12-31 -2.78
2018-09-30 -3.72
2018-06-30 -6.31
2018-03-31 -10.59
2017-12-31 -9.10
2016-12-31 -5.28

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Evelo Biosciences will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Evelo Biosciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Evelo Biosciences has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Evelo Biosciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Evelo Biosciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Evelo Biosciences does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Evelo Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Evelo Biosciences's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Evelo Biosciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Evelo Biosciences Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:EVLO Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 -72.54 20.93 53.71
2019-03-31 -68.27 20.06 48.42
2018-12-31 -60.88 18.22 39.89
2018-09-30 -55.31 15.56 34.62
2018-06-30 -49.34 13.02 28.74
2018-03-31 -40.45 9.49 23.25
2017-12-31 -34.13 7.57 19.96
2016-12-31 -14.98 3.89 9.13

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Evelo Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Evelo Biosciences has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Evelo Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Evelo Biosciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Evelo Biosciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Evelo Biosciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Evelo Biosciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Evelo Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Evelo Biosciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Evelo Biosciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 7.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Evelo Biosciences Company Filings, last reported 1 month ago.

NasdaqGS:EVLO Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 100.09 15.14 113.47
2019-03-31 118.88 14.83 129.44
2018-12-31 136.95 12.31 147.92
2018-09-30 150.76 14.16 164.33
2018-06-30 165.05 14.75 178.90
2018-03-31 101.86 14.72 114.31
2017-12-31 29.40 9.97 38.25
2016-12-31 5.65 9.93 15.54
  • Evelo Biosciences's level of debt (15.1%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Evelo Biosciences's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Evelo Biosciences has sufficient cash runway for 1.7 years based on current free cash flow.
  • Evelo Biosciences has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 54.6% each year.
X
Financial health checks
We assess Evelo Biosciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Evelo Biosciences has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Evelo Biosciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Evelo Biosciences dividends.
If you bought $2,000 of Evelo Biosciences shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Evelo Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Evelo Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:EVLO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2009 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:EVLO Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Evelo Biosciences has not reported any payouts.
  • Unable to verify if Evelo Biosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Evelo Biosciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Evelo Biosciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Evelo Biosciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Evelo Biosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Evelo Biosciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Evelo Biosciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Simba Gill
COMPENSATION $4,469,066
AGE 54
TENURE AS CEO 3.9 years
CEO Bio

Dr. Balkrishan Gill, also known as Simba, Ph.D. serves as Independent Non-Executive Director of Realm Therapeutics plc since 2019. He serves as the Chief Executive Officer of Evelo Biosciences, Inc. Dr. Gill serves as Chief Executive Officer and President of Evelo Therapeutics, Inc. He serves as the Executive Chair and Chief Executive Officer at Blackfynn Inc. He is Venture Partner at Flagship Ventures. He joined Flagship Pioneering in 2015 and focuses on providing strategic counsel and support to portfolio companies. Dr. Gill founded moksha8 Pharmaceuticals, Inc. and served as its Chief Executive Officer and President. While at moksha8, he founded a biosimilar antibody company called fourteen22. Dr. Gill was an Entrepreneur in Residence and Venture Partner at TPG Growth/Texas Pacific Group Growth. He was involved in several of TPG's healthcare investments in the Emerging Markets including ShangPharma and Agria. Dr. Gill served as Special Advisor of Maxygen Inc. since December 2005. He was employed at Avidia. He was co-head of Worldwide Marketing for Recormon. He also led corporate and market development and strategy from inception to commercialization of the Elecsys immunodiagnostics system. He served as an Executive Officer of Roche Diagnostics GmbH. Prior to joining TPG, Dr. Gill served as President of Maxygen Inc. from April 2000 to December 2005. Dr. Gill joined Maxygen Inc. in July 1998 as Chief Financial Officer and Senior Vice President of Business Development. Dr. Gill has previously led Corporate Development activities in a number of biotech companies and formed many significant strategic partnerships with several of the world's major pharmaceutical, agricultural and chemical companies including Roche, Pfizer, AstraZeneca, Novo, Novartis, Lundbeck and DuPont. Before joining Maxygen, Dr. Gill served as Vice President of Business Development at Valentis Inc. (a/k/a, Megabios Corp.), from November 1996 to July 1998. Dr. Gill began his career at Celltech, focused on antibody research. From November 1995 to November 1996, Dr. Gill served as Director of Business Development at Systemix Inc. Before joining Systemix, Dr. Gill held a variety of positions at Boehringer Mannheim, including Global Product Manager for erythropoietin, Manager of Corporate Business Development and Director of New Diagnostics Program Management. He also served as Global Marketing Director at Boehringer Mannheim (now Roche). He served as Non-Executive Director of Realm Therapeutics Plc. until July 31, 2019. He served as Independent Non-Executive Director of PuriCore Plc ( Realm Therapeutics Plc) since March 1, 2016. He serves as a Director of Evelo Therapeutics, Inc. He serves as a Director of Evelo Biosciences, Inc. He served as a Director of Verdia Inc., moksha8 Pharmaceuticals Inc. and Codexis Inc. He has a long track record of identifying new technologies and geographies for high-growth business opportunities. Dr. Gill received his Ph.D. in immunology and antibody engineering at King's College, London University in collaboration with the U.K. biotechnology company Celltech and his M.B.A. from INSEAD in Fontainbleau, France.

CEO Compensation
  • Simba's compensation has increased whilst company is loss making.
  • Simba's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Evelo Biosciences management team in years:

1.5
Average Tenure
55
Average Age
  • The average tenure for the Evelo Biosciences management team is less than 2 years, this suggests a new team.
Management Team

Noubar Afeyan

TITLE
Co-founder & Chairman of the Board
COMPENSATION
$50K
AGE
56

Simba Gill

TITLE
President
COMPENSATION
$4M
AGE
54
TENURE
3.9 yrs

Jonathan Poole

TITLE
CFO & Treasurer
COMPENSATION
$3M
AGE
44
TENURE
1.4 yrs

Duncan McHale

TITLE
Chief Medical Officer
COMPENSATION
$2M
AGE
52
TENURE
1.5 yrs

Mark Bodmer

TITLE
Chief Scientific Officer and President of Research & Development
COMPENSATION
$936K
AGE
61
TENURE
3.3 yrs

Stefan Riley

TITLE
Head of Investor Relations

Daniel Char

TITLE
General Counsel & Secretary
AGE
58
TENURE
0.8 yrs

Michael Garcia-Webb

TITLE
Head of People & Operational Excellence
TENURE
1.5 yrs

Kareem Reda

TITLE
Head of Business Development & Corporate Strategy

Chun Zhang

TITLE
Head of Process Development & Manufacturing
TENURE
2.1 yrs
Board of Directors Tenure

Average tenure and age of the Evelo Biosciences board of directors in years:

2.5
Average Tenure
57
Average Age
  • The average tenure for the Evelo Biosciences board of directors is less than 3 years, this suggests a new board.
Board of Directors

Simba Gill

TITLE
President
COMPENSATION
$4M
AGE
54
TENURE
3.9 yrs

David Epstein

TITLE
Director
COMPENSATION
$28K
AGE
57
TENURE
2.4 yrs

Noubar Afeyan

TITLE
Co-founder & Chairman of the Board
COMPENSATION
$50K
AGE
56
TENURE
5.3 yrs

Theo Melas-Kyriazi

TITLE
Director
COMPENSATION
$39K
AGE
60
TENURE
2.5 yrs

David Perry

TITLE
Director
COMPENSATION
$25K
AGE
51
TENURE
3.2 yrs

Ara Darzi

TITLE
Director
COMPENSATION
$486K
AGE
58
TENURE
1.5 yrs

Nancy Simonian

TITLE
Director
COMPENSATION
$364K
AGE
58
TENURE
1.3 yrs

Jose-Carlos Gutiérrez-Ramos

TITLE
Director
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Evelo Biosciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Evelo Biosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Can We See Significant Institutional Ownership On The Evelo Biosciences Inc (NASDAQ:EVLO) Share Register?

Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … We also tend to see lower insider ownership in companies that were previously publicly owned. … With a market capitalization of US$305m, Evelo Biosciences is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

Evelo Biosciences Inc's (NASDAQ:EVLO) Profit Outlook

Evelo Biosciences Inc's (NASDAQ:EVLO):. … Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. … The company’s loss has recently broadened since it announced a -US$34.13m loss in the full financial year, compared to the latest trailing-twelve-month loss of -US$40.45m, moving it further away from breakeven

Simply Wall St -

Company Info

Description

Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases. The company is also involved in developing EDP150, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. Evelo Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Details
Name: Evelo Biosciences, Inc.
EVLO
Exchange: NasdaqGS
Founded: 2014
$195,883,098
32,059,427
Website: http://www.evelobio.com
Address: Evelo Biosciences, Inc.
620 Memorial Drive,
Suite 200 West,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS EVLO Common Stock Nasdaq Global Select US USD 09. May 2018
Number of employees
Current staff
Staff numbers
75
Evelo Biosciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/08/18 01:10
End of day share price update: 2019/08/16 00:00
Last estimates confirmation: 2019/08/09
Last earnings filing: 2019/08/06
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.